Biotechnology Entrepreneurship Boot Camp
Sponsored by Pepper Hamilton, LLP
This three-day course is designed for entrepreneurial scientists, CEO's, CSO's, and business development professionals of early stage life science companies and academic scientists who are aspiring entrepreneurs.
Registration fee: $295 (includes the three-day course and lunch)
Sunday, June 26 through mid-day Tuesday, June 28, 2011
Agenda
Sunday, June 26, 2011
Session 3: 9:00 am - 10:15 am
Moderator and Lecturers: Arthur Boni, Ph.D.: John R. Thorne Chair of
Entrepreneurship Tepper School of Business, Director, Donald H. Jones Center
for Entrepreneurship, Carnegie Mellon University
Panayiottis P. Constantinides, Ph.D.: CEO, BPDDC, LLC
Project, Product, or Company: Assessment and Qualification
of Technologies as a Basis for a Business Startup
Forming a company around a technology is relatively easy. Staffing and capitalizing
it is another story. Savvy employees, astute venture capitalist and selective prospective
strategic partners know that companies without technological “critical mass” sufficient to
bring a series of product to the market are unsustainable. This session will provide tools
and a contextual framework as to how technologies can be assessed for capitalization
and partnering.
10:15 am - 11:00 am
Break-out with refreshments for Case Discussion followed by
group recommendations
Session 4: 11:00 am - 12:00 pm
Reimbursement and Pricing Strategies
It is never too early to assess how the market will respond to products, especially as it
relates to pricing and reimbursement. You'll learn the fundamentals of pharmaceutical
pricing and reimbursement strategies.
12:00 - 1:00 pm: Lunch
Session 5: 1:00 pm - 3:00 pm
Moderator - Stephen Sammut: Venture Partner & Senior Fellow at
Burrill & Company
Faculty - Raymond A. Miller, JD: Partner, Pepper Hamilton LLP
Kathryn Doyle, Ph.D., JD: Partner and Chair, Riverside Law LLP
What Every Investigator Must Know about IP in Biotechnology Startups
You'll gain invaluable insight into the specific issues confronting investigators, entrepreneurs, investors and their patent attorneys. Additionally, the speakers will describe the prevailing treatment by the PTO and the courts of specific issues and implications such as the doctrine of equivalents, gene sequencing, process patents, international issues, etc. The two biotechnology patent attorneys will also describe the intellectual property concerns of licensor and licensee.
3:00 pm - 3:15 pm: Break
Session 6: 3:15 pm - 5:00 pm
Moderator - Jeffrey Libson, JD: Partner at Pepper Hamilton LLP
Faculty - James G. Kenimer, Ph.D.: President and CEO, Biologics Consulting Group
Jim Ackland: President, Global Biosolutions
Regulatory Planning and the Implications for Strategy and Financing
You'll learn specific insight into planning for FDA regulations in light of strategy,
financial needs, and the concerns of prospective partners and investors. The session
features two internationally know authorities in regulatory affairs.
5:00 pm - 5:10 pm: Break
Session 7: 5:10 pm - 6:30 pm
Moderator and Lecturer: Arthur A. Boni, Ph.D.
Building an Entrepreneurial Management Team
Team building in biotechnology companies is the most challenging task for entrepreneurs, and the backbone of venture capitalists’ decision to invest or not to invest. You'll explore the issues in forming an entrepreneurial team of a start-up or early stage company and approaches to successful team formation and management of the team. The panelists represent the perspective of a CEO, CSO, and a venture capitalist.
6:30 pm - 7:30 pm: Reception
Monday, June 27th, 2011
7:45 am - 8:15 am: Breakfast and Registration
Sessions 8 & 9: 8:15 am - 9:15 am
Moderator and Lecturer: Arthur A. Boni, Ph.D.
Faculty Commentators: James Foley, Ph.D.: CEO, Aqua Partners and former head of Business Development, BristolMyers Squibb
Benjamin Chen, Ph.D.: Managing Partner, Ignatius Transaction Partners
Jeffrey Libson: Partner, Pepper Hamilton LLP, Lecturer, Wharton School
Kent Gossett, DVM, Ph.D., MBA: Partner, SR One, Ltd. (the venture fund of GlaxoSmithKline)
The Business Plan and Pitch Book in the Fund Raising Process
Experienced entrepreneurs and their investors openly recognize that within a year of operating, few companies resemble their original business plan. You'll be provided a framework for developing a pitch and the essentials of a business plan. An entrepreneur will present a partnering pitch for his/her company to a panel of early stage business development professionals who will make a real-time critique and recommendations. Boot Camp participants will be invited to share their own views as well.
Session 10: 9:15 am - 10:30 am
Combined break with small group discussion of Session 8
Session 11: 10:30 am - 12:15 pm
Faculty - Benjamin Chen, PhD.: Managing Partner, Ignatius Transaction Partners
James Foley, Ph.D.: CEO, Aqua Partners, former head of Business Development, BristolMyers Squibb
Jeffrey Libson, JD: Partner, Pepper Hamilton LLP, Lecturer, Wharton School
Licensing, Partnering, Strategic Alliances and University Relationships
You'll learn how to position and prepare a company for a licensing/alliance campaign. The session will be opened with a presentation on the key points of developing and managing the relationship, and the strategic importance of forming alliances in this industry. You'll gain insights on the academic perspective on licensing and expectations, as well as the strategic elements of out-licensing and partnering, and the most effective ways to market and manage a relationship. The session will also offer a legal perspective on licensing transactions.
12:30 pm - 1:45 pm: Lunch
Session 12: 1:45 pm - 3:45 pm
Moderator - Stephen Sammut: Venture Partner & Senior Fellow at Burrill & Company
Speakers - Ashley J. Stevens, D.Phil (Oxon), CLP, Special Assistant to the Vice President for Research Technology Development, Senior Research Associate, ITEC
Christopher Miller, JD: Partner, Pepper Hamilton LLP
Capitalization of the Venture
CEO's and CSO's of biotechnology companies spend as much time raising capital as managing their company. Biotechnology companies have unique issues in raising capital because their risk profiles differ from companies in most other industries. Biotechnology entrepreneurs and their venture capitalists, therefore have a unique relationship and dynamic. An attorney specializing in company formation and capitalization will join the panel to provide you with legal perspectives.
3:45 pm - 4:15 pm: Break
Session 13: 4:15 pm - 5:30 pm
Introduction by Stephen Sammut: National Co-Chair, Venture Partner, Burrill & Company, Senior Fellow, Wharton School
Keynote Address: David U'Prichard, Ph.D.: President and CEO, Druid Consulting, LLC, Venture Partner, Red Abbey Ventures, Former Chairman, Research and Development, GlaxoSmithKline
Tuesday, June 28, 2011
Session 14: 8:30 am - 9:30 am
Faculty Commentator: Elaine V. Jones, Ph.D., Executive Director, Venture Capital Worldwide Business Development, Pfizer, Inc.
Local Company Pitch to Venture Capitalists
Session 15: 9:30 am - 10:30 am
Combined break with small group discussion of Session 15
Session 16: 10:30 am - 11:30 am
Exit Strategies
Session 17: 11:30 am - 12:30 pm
Mock Term Sheet Negotiation
Closing Remarks: 12:30 pm - 12:45 pm
Complete Agenda
Reserve your spot, as space is limited to 85 people!